205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-7.99%
Negative revenue growth while ADI stands at 21.55%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-8.87%
Negative gross profit growth while ADI is at 13.20%. Joel Greenblatt would examine cost competitiveness or demand decline.
-18.98%
Negative EBIT growth while ADI is at 9.30%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-18.98%
Negative operating income growth while ADI is at 9.30%. Joel Greenblatt would press for urgent turnaround measures.
-12.32%
Negative net income growth while ADI stands at 278.71%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-9.09%
Negative EPS growth while ADI is at 275.76%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-9.26%
Negative diluted EPS growth while ADI is at 281.25%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
-3.28%
Share reduction while ADI is at 0.00%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-3.79%
Reduced diluted shares while ADI is at 0.00%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
-0.35%
Both companies cut dividends. Martin Whitman would look for a common factor, such as cyclical downturn or liquidity constraints.
-54.95%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-66.02%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
75.89%
10Y revenue/share CAGR at 75-90% of ADI's 98.58%. Bill Ackman would press for new markets or product lines to narrow the gap.
88.01%
5Y revenue/share CAGR 1.25-1.5x ADI's 59.44%. Bruce Berkowitz would verify if cost efficiency or pricing power supports this advantage.
41.12%
3Y revenue/share CAGR 1.25-1.5x ADI's 32.76%. Bruce Berkowitz might see better product or regional expansions than the competitor.
1774.64%
10Y OCF/share CAGR above 1.5x ADI's 161.42%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
311.93%
5Y OCF/share CAGR above 1.5x ADI's 104.62%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
57.10%
3Y OCF/share CAGR at 50-75% of ADI's 90.59%. Martin Whitman would suspect weaker recent execution or product competitiveness.
6975.22%
Net income/share CAGR above 1.5x ADI's 795.19% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
612.67%
5Y net income/share CAGR similar to ADI's 650.15%. Walter Schloss might see both on parallel mid-term trajectories.
106.47%
Below 50% of ADI's 333.18%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
93.88%
10Y equity/share CAGR at 75-90% of ADI's 120.71%. Bill Ackman would push for either higher ROE or more earnings retention to catch the competitor.
15.72%
Positive 5Y equity/share CAGR while ADI is negative. John Neff might see a clear edge in retaining earnings or managing capital better.
6.14%
Positive short-term equity growth while ADI is negative. John Neff sees a strong advantage in near-term net worth buildup.
373.82%
Dividend/share CAGR of 373.82% while ADI is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
352.76%
Dividend/share CAGR of 352.76% while ADI is zero. Bruce Berkowitz sees a minor advantage in stepping up distributions, even modestly.
296.48%
3Y dividend/share CAGR 1.25-1.5x ADI's 199.35%. Bruce Berkowitz checks if the company's short-term profits or payout policy justify these higher hikes.
-4.19%
Firm’s AR is declining while ADI shows 5.04%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
11.28%
We show growth while ADI is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
-2.60%
Negative asset growth while ADI invests at 5.48%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
2.17%
BV/share growth above 1.5x ADI's 0.05%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
No Data
No Data available this quarter, please select a different quarter.
0.98%
R&D dropping or stable vs. ADI's 61.57%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
3.08%
SG&A declining or stable vs. ADI's 7.77%. David Dodd sees better overhead efficiency if it doesn't hamper revenue.